This may result in de novo hypertension in 30% to 80% of patients after VPI therapy.2,4,5,6,8 Elevated blood pressure caused by preexisting hypertension or inhibition of the VEGF pathway may contribute to the development of AA and AD.24,25 Previous studies have found that the risk of VPI-associated AD was similar in patients with and without preexisting hypertension.8,9 Our study also indicated that the risk of AA and AD remained significantly higher in patients receiving VPIs after adjusting for preexisting hypertension. The gene discussed is VEGFA; the disease is hypertensive disorder.